文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

意大利 2021 年 11 月至 2022 年 2 月期间奥密克戎变异株相对于德尔塔变异株导致 COVID-19 重症风险降低。

Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 - February 2022).

机构信息

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; Department of Statistics, Sapienza University of Rome, Rome, Italy.

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

出版信息

Int J Infect Dis. 2023 Apr;129:135-141. doi: 10.1016/j.ijid.2023.01.027. Epub 2023 Jan 26.


DOI:10.1016/j.ijid.2023.01.027
PMID:36708869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9877142/
Abstract

OBJECTIVES: During 2022, Omicron became the dominant SARS-CoV-2 variant in Europe. This study aims to assess the impact of such variant on severe disease from SARS-CoV-2 compared with the Delta variant in Italy. METHODS: Using surveillance data, we assessed the risk of developing severe COVID-19 with Omicron infection compared with Delta in individuals aged ≥12 years using a multilevel negative binomial model adjusting for sex, age, vaccination status, occupation, previous infection, weekly incidence, and geographical area. We also analyzed the interaction between the sequenced variant, age, and vaccination status. RESULTS: We included 21,645 cases of SARS-CoV-2 infection where genome sequencing found Delta (10,728) or Omicron (10,917), diagnosed from November 15, 2021 to February 01, 2022. Overall, 3,021 cases developed severe COVID-19. We found that Omicron cases had a reduced risk of severe COVID-19 compared with Delta cases (incidence rate ratio [IRR] = 0.77; 95% confidence interval [CI]: 0.70-0.86). The largest difference was observed in cases aged 40-59 (IRR = 0.66; 95% CI: 0.55-0.79), while no protective effect was found in those aged 12-39 (IRR = 1.03; 95% CI: 0.79-1.33). Vaccination was associated with a lower risk of developing severe COVID-19 in both variants. CONCLUSION: The Omicron variant is associated with a lower risk of severe COVID-19 compared to infection with the Delta variant, but the degree of protection varies with age.

摘要

目的:2022 年期间,奥密克戎(Omicron)成为欧洲主要的 SARS-CoV-2 变异株。本研究旨在评估与意大利的德尔塔(Delta)变异株相比,奥密克戎变异株对 SARS-CoV-2 重症疾病的影响。

方法:使用监测数据,我们使用多水平负二项式模型评估了 12 岁以上个体中奥密克戎感染与德尔塔感染相比发生重症 COVID-19 的风险,该模型调整了性别、年龄、疫苗接种状态、职业、既往感染、每周发病率和地理区域。我们还分析了测序变异、年龄和疫苗接种状态之间的相互作用。

结果:我们纳入了 21645 例 SARS-CoV-2 感染病例,其中基因组测序发现德尔塔(10728 例)或奥密克戎(10917 例),诊断时间为 2021 年 11 月 15 日至 2022 年 2 月 1 日。总体而言,3021 例发生了重症 COVID-19。我们发现奥密克戎病例发生重症 COVID-19 的风险较德尔塔病例降低(发病率比[IRR] = 0.77;95%置信区间[CI]:0.70-0.86)。在 40-59 岁的病例中差异最大(IRR = 0.66;95% CI:0.55-0.79),而在 12-39 岁的病例中未发现保护作用(IRR = 1.03;95% CI:0.79-1.33)。在两种变异株中,疫苗接种均与重症 COVID-19 风险降低相关。

结论:与感染德尔塔变异株相比,奥密克戎变异株与重症 COVID-19 的风险较低相关,但保护程度随年龄而异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa9c/9877142/bb71f4605628/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa9c/9877142/bb71f4605628/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa9c/9877142/bb71f4605628/gr1_lrg.jpg

相似文献

[1]
Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 - February 2022).

Int J Infect Dis. 2023-4

[2]
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.

PLoS Med. 2022-9

[3]
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.

PLoS Med. 2022-11

[4]
Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.

PLoS Med. 2022-11

[5]
Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.

Euro Surveill. 2023-3

[6]
Impact of SARS-CoV-2 Omicron and Delta variants in patients requiring intensive care unit (ICU) admission for COVID-19, Northern Italy, December 2021 to January 2022.

Respir Med Res. 2023-6

[7]
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.

MMWR Morb Mortal Wkly Rep. 2022-1-28

[8]
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.

JAMA. 2022-2-15

[9]
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.

MMWR Morb Mortal Wkly Rep. 2022-2-11

[10]
Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.

Epidemiol Infect. 2022-12-20

引用本文的文献

[1]
Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility.

Biomed Rep. 2025-5-20

[2]
Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis.

J Glob Health. 2025-2-7

[3]
Sex Differences in Long COVID.

JAMA Netw Open. 2025-1-2

[4]
A longitudinal study to COVID-19 infection among university students: Physical fitness changes and psychological responses.

J Exerc Sci Fit. 2025-1

[5]
Dynamics of an SVEIR transmission model with protection awareness and two strains.

Infect Dis Model. 2024-10-10

[6]
Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.

J Korean Med Sci. 2024-9-30

[7]
Incidence and Predictors of Healthcare-Associated Infections in Patients Admitted to a Temporary Intensive Care Unit during the COVID-19 Pandemic Waves: A Two-Year (2021-2023) Retrospective Cohort Study in Rome, Italy.

Antibiotics (Basel). 2024-9-4

[8]
Increasing situational awareness through nowcasting of the reproduction number.

Front Public Health. 2024

[9]
Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection.

iScience. 2024-5-28

[10]
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.

Ther Adv Infect Dis. 2024-3-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索